1 Brand-New (Good) Reason to Buy Viking Therapeutics Stock Now
Viking Therapeutics (NASDAQ: VKTX) is on a tear this year, with shares catapulting upward by 340% thanks to good data (and high expectations) from one of its mid-stage clinical trials testing a weight loss drug. The data readouts from that program alone were enough to convince quite a few investors to buy the stock.
And now there's a brand-new reason to invest -- perhaps an even better one than before. Let's investigate what's new and why it matters.
For the uninitiated, Viking's program -- called VK2735 -- is a highly promising therapy for obesity. It's being evaluated in two formulations in clinical trials, one that is injected on a weekly basis and the other being a once-daily pill.
Source Fool.com
Viking Therapeutics Inc Stock
€58.10
2.370%
We see a rather positive sentiment for Viking Therapeutics Inc with 6 Buy predictions and 1 Sell predictions.
With a target price of 110 € there is a hugely positive potential of 89.33% for Viking Therapeutics Inc compared to the current price of 58.1 €.
